Abivax's experimental ulcerative colitis treatment, obefazimod, demonstrated significant efficacy in a Phase 3 trial, achieving clinical remission in over 50% of patients. However, the company's shares fell due to reported cancer cases among treated patients.

• 01The Phase 3 trial involved 580 patients who previously responded to shorter trials.
• 0250.8% of patients on a 25-mg dose and 51.3% on a 50-mg dose achieved clinical remission.
• 03Only 10.4% of patients on placebo reached clinical remission.
• 04The trial reported the highest placebo-adjusted remission rates for long-term ulcerative colitis studies.
• 05Concerns about cancer cases among treated patients negatively impacted Abivax's stock.